Transaxillary compared with transcarotid ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
Titre :
Transaxillary compared with transcarotid access for TAVR: a propensity-matched comparison from a French multicentre registry
Auteur(s) :
Debry, Nicolas [Auteur]
Institut Coeur Poumon [CHU Lille]
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Trimech, Talel Raouf [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Gandet, Thomas [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Vincent, Flavien [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Hysi, Ilir [Auteur]
Centre Hospitalier de Lens
Delhaye, Cédric [Auteur]
Institut Coeur Poumon [CHU Lille]
Cayla, Guillaume [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Koussa, Mohamad [Auteur]
Institut Coeur Poumon [CHU Lille]
Juthier, Francis [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Leclercq, Florence [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Pécheux, Max [Auteur]
Centre Hospitalier de Lens
Ghostine, Saïd [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Service de Biostatistiques [CHRU Lille]
Modine, Thomas [Auteur]
Institut Coeur Poumon [CHU Lille]
van Belle, Eric [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Trimech, Talel Raouf [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Gandet, Thomas [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Vincent, Flavien [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Hysi, Ilir [Auteur]
Centre Hospitalier de Lens
Delhaye, Cédric [Auteur]
Institut Coeur Poumon [CHU Lille]
Cayla, Guillaume [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Koussa, Mohamad [Auteur]
Institut Coeur Poumon [CHU Lille]
Juthier, Francis [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Leclercq, Florence [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Pécheux, Max [Auteur]
Centre Hospitalier de Lens
Ghostine, Saïd [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Service de Biostatistiques [CHRU Lille]
Modine, Thomas [Auteur]
Institut Coeur Poumon [CHU Lille]
van Belle, Eric [Auteur]
Institut Coeur Poumon [CHU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Titre de la revue :
EuroIntervention
Pagination :
842-849
Éditeur :
EuroPCR
Date de publication :
2020-11
ISSN :
1774-024X
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Cardiologie et système cardiovasculaire
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie
Résumé en anglais : [en]
Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative ...
Lire la suite >Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative by comparing their outcomes using a propensity-matched comparison in a French multicentre registry.Methods and results: From 2010 to 2018, a French multicentre prospective registry included 502 patients, with 374 undergoing TC-TAVR and 128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 with patients treated through the TC route by using a propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was mortality at one-month follow-up. The second outcome was one-month stroke/transient ischaemic attack (TIA). In propensity-matched analyses, the incidence of the primary outcome was similar in the TAx and TC groups (TAx 5.5% vs TC 4.5%, OR 1.23, 95% CI: 0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%, OR 0.52, 95% CI: 0.14-1.84). Minor bleeding (2.7% vs 9.3%, OR 0.26, 95% CI: 0.07-0.92) and main access haematoma (3.6% vs 10.3%, OR 0.034, 95% CI: 0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and one-year mortality did not differ according to the different routes.Conclusions: One-month mortality, one-month stroke/TIA and one-year mortality are similar with TAx-TAVR and TC-TAVR. However, TC-TAVR is accompanied by more minor bleeding and main access haematoma compared with the transaxillary route.Lire moins >
Lire la suite >Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative by comparing their outcomes using a propensity-matched comparison in a French multicentre registry.Methods and results: From 2010 to 2018, a French multicentre prospective registry included 502 patients, with 374 undergoing TC-TAVR and 128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 with patients treated through the TC route by using a propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was mortality at one-month follow-up. The second outcome was one-month stroke/transient ischaemic attack (TIA). In propensity-matched analyses, the incidence of the primary outcome was similar in the TAx and TC groups (TAx 5.5% vs TC 4.5%, OR 1.23, 95% CI: 0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%, OR 0.52, 95% CI: 0.14-1.84). Minor bleeding (2.7% vs 9.3%, OR 0.26, 95% CI: 0.07-0.92) and main access haematoma (3.6% vs 10.3%, OR 0.034, 95% CI: 0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and one-year mortality did not differ according to the different routes.Conclusions: One-month mortality, one-month stroke/TIA and one-year mortality are similar with TAx-TAVR and TC-TAVR. However, TC-TAVR is accompanied by more minor bleeding and main access haematoma compared with the transaxillary route.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :